PFIZER INC Deferred Tax Assets, Tax Deferred Expense
PFIZER INC (PFE) had Deferred Tax Assets, Tax Deferred Expense of $3.52 billion as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpense · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense $3.52B.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense $3.29B; Deferred Tax Assets, Tax Deferred Expense as first filed $2.99B.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense $2.66B.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense $1.67B; Deferred Tax Assets, Tax Deferred Expense as first filed $1.77B.
| Period end | Deferred Tax Assets, Tax Deferred Expense | Deferred Tax Assets, Tax Deferred Expense as first filed |
|---|---|---|
| 2025-12-31 | $3.52B 10-K · filed 2026-02-26 | |
| 2024-12-31 | $3.29B 10-K · filed 2026-02-26 | $2.99B 10-K · filed 2025-02-27 |
| 2023-12-31 | $2.66B 10-K · filed 2025-02-27 | |
| 2022-12-31 | $1.67B 10-K · filed 2024-02-22 | $1.77B 10-K · filed 2023-02-23 |
| 2021-12-31 | $1.89B 10-K · filed 2023-02-23 | $4.09B 10-K · filed 2022-02-24 |
| 2020-12-31 | $3.11B 10-K · filed 2022-02-24 | $3.09B 10-K · filed 2021-02-25 |
| 2019-12-31 | $1.92B 10-K · filed 2021-02-25 | $2.19B 10-K · filed 2020-02-27 |
| 2018-12-31 | $1.66B 10-K · filed 2020-02-27 | |
| 2017-12-31 | $1.84B 10-K · filed 2019-02-28 | $1.59B 10-K · filed 2018-02-22 |
| 2016-12-31 | $2.18B 10-K · filed 2018-02-22 | |
| 2015-12-31 | $2.25B 10-K · filed 2017-02-23 | |
| 2014-12-31 | $2.00B 10-K · filed 2016-02-29 | |
| 2013-12-31 | $1.91B 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |